HUMA240517C7500
- 0.04
- 0.000.00%
Humacyte Newsroom
URBN, SHLS and VSAT Are Among After Hour Movers
Humacyte(HUMA.US) Director Buys US$50,030.25 in Common Stock
$Humacyte(HUMA.US)$ Director Wallace Max N. purchased 8,005 shares of common stock on May 20, 2024 at an average price of $6.25 for a total value of $50,030.25.Source: Announcement What is statement o
This Humacyte Insider Increased Their Holding By 91% Last Year
CRSP, NYMT and SBRA Are Among After Hour Movers
Humacyte(HUMA.US) Director Buys US$667.5K in Common Stock
$Humacyte(HUMA.US)$ Director Binder Gordon M purchased 100K shares of common stock on May 15, 2024 at an average price of $6.68 for a total value of $667.5K.Source: Announcement What is statement of c
OPEN, BCRX and AWIN Among Pre-market Gainers
Individual Investors Who Own 53% Along With Institutions Invested in Humacyte, Inc. (NASDAQ:HUMA) Saw Increase in Their Holdings Value Last Week
Key Insights Significant control over Humacyte by individual investors implies that the general public has more power to influence management and governance-related decisions The top 25 shareholders
10-Q: Quarterly report
Analysts Are Bullish on Top Healthcare Stocks: Humacyte (HUMA), Rallybio (RLYB)
Express News | Benchmark Reiterates Buy on Humacyte, Maintains $15 Price Target
Humacyte Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 215.79% Benchmark → $15 Reiterates Buy → Buy 04/01/2024 47.37% Cantor Fitzgerald → $7 Reiterate
Benchmark Co. Keeps Their Buy Rating on Humacyte (HUMA)
Humacyte Inc (HUMA) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...
Humacyte to Participate at Upcoming Investor Conferences in May
PDF Version DURHAM, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human
Humacyte Inc (HUMA) Q1 2024 Earnings: Aligns With Analyst Projections Amid Strategic Advances
Peering Into Humacyte's Recent Short Interest
Humacyte's (NYSE:HUMA) short percent of float has fallen 13.81% since its last report. The company recently reported that it has 3.94 million shares sold short, which is 4.37% of all regular shares th
Insiders, Hedge Funds, and Politicians Trading Humacyte Stock (NDAQ:HUMA) in Q1 2024
Express News | Humacyte Inc: Biologics License Application (Bla) for Hav™ Accepted by FDA
Express News | Humacyte Inc: Raised Approximately $43 Mln in Net Proceeds From Public Offering of Common Stock
Humacyte Reported Cash and Cash Equivalents of $115.5M as of March 31 >HUMA
Humacyte Reported Cash and Cash Equivalents of $115.5M as of March 31 >HUMA